Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
Nathanson, Katherine L. , Offit, Kenneth , Couch, Fergus J. , Nathanson, Katherine L

Science | March 27, 2014 | Volume: 343 | Issue: 6178 | Pages: 1466-1470

10.1126/science.1251827 | PMID 24675953 Get It

The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1 , BRCA2 , and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2 , the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.
A159: The Autoimmune Genetic Architecture of Childhood Onset Rheumatoid Arthritis
Marion, Miranda C. , Sudman, Marc , Pichavant, Mina, Ponder, Lori, Reed, Ann M. , Wallace, Carol A., Becker, Mara L. , Rosenberg, Alan , Punaro, Marilynn, Mellins, Elizabeth , Nelson, J. Lee , Rygg, Marite , Cutler, David J. , Bohnsack, John F. , Thompson, Susan D. , Langefeld, Carl D. , Prahalad, Sampath , Cobb, Joanna E. , Hinks, Anne , Yeung, Rae S. M. , Videm, Vibeke , Nordal, Ellen Berit , Brown, Matthew A. , Thomson, Wendy

Arthritis & Rheumatology | March 27, 2014 | Volume: 66 | Issue: S3 | Pages: No page available

10.1002/art.38585 Get It

Background/Purpose:Genome‐wide association studies have identified susceptibility loci for many autoimmune diseases, including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). About 5% of children with JIA have rheumatoid factor positive arthritis that is phenotypically similar to adult seropositive RA, thus representing childhood onset RA (CORA). To understand the genetic architecture of CORA risk relative to other autoimmune diseases, we genotyped CORA cases and controls on the Immunochip, a custom array designed by the Immunochip Consortium to fine map autoimmune disease‐associated loci shared across 11 autoimmune phenotypes.Methods:Genotyping was completed on 340 CORA cases (mean onset age: 10.2 ± 4.2 yrs) and 11624 controls. Standard SNP and sample QC was performed (e.g., removing samples with call rate <98%, admixture outliers). To test for SNP association with CORA a logistic regression model was computed with Caucasian admixture proportions (ADMIXTURE) as covariates (SNPLash). False discovery rate (FDR) adjusted p‐values (PFDR) are reported to account for the actual number of tests computed.Results:SNP rs3129769, near HLA DRB1 was the most significantly associated (PFDR <3×10‐25), and is in linkage disequilibrium with the HLA DRB1 SNP reported in RA (rs660895, PFDR <1×10‐24). Outside the HLA region, 28 regions had ≥1 SNP meeting genome‐wide significance (PFDR<0.05). The best signal of association was on 22q13 (rs9610687, OR = 0.57, PFDR < 0.0002) near IL2RB, followed by the PTPN22 locus (rs6679677, OR = 1.83, PFDR < 0.0005), an intergenic SNP on chromosome 4 (rs970036, OR = 1.78, PFDR < 0.002) and an intronic SNP (19p13, rs3787016 PFDR < 0.002) in the POLR2E gene, which encodes a subunit of RNA polymerase II. Some loci which have previously been implicated in RA had evidence of association including MMEL (rs751358 PFDR < 0.003), IRF5 (rs4731531 PFDR < 0.006) and CCR6 (rs11575078 PFDR < 0.03). In addition using the FDR‐based threshold we identified several potential SNPs (rs10918214, 1q23; rs28491312, 14q31) not previously implicated in RA.Conclusion:Immunochip analysis of the largest cohort of CORA investigated to date has confirmed the HLA DRB1 association and identified several other loci associated with CORA. Comparisons among loci associated with CORA and those identified in RA and other forms of JIA are underway and will help delineate the unique genetic factors for CORA susceptibility.
Faculty Opinions recommendation of Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 27, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718297859.793492606 Get It

Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets
Raz, Limor , Jayachandran, Muthuvel , Heit, John A. , Miller, Virginia M. , Hunter, Larry W.

Physiological Reports | March 27, 2014 | Volume: 2 | Issue: 3 | Pages: e00275

10.1002/phy2.275 | PMID 24760527 Get It

Intra-articular decorin influences the fibrosis genetic expression profile in a rabbit model of joint contracture
Grill, Diane E. , Kolbert, Christopher P., An, Kai‐Nan , Steinmann, Scott P. , Morrey, B.F. , Abdel, Matthew P. , Morrey, Mark E. , Barlow, Jonathan D. , Sánchez‐Sotelo, Joaquín

Bone & Joint Research | March 27, 2014 | Volume: 3 | Issue: 3 | Pages: 82-88

10.1302/2046-3758.33.2000276 | PMID 24671942 Get It

Objectives The goal of this study was to determine whether intra-articular administration of the potentially anti-fibrotic agent decorin influences the expression of genes involved in the fibrotic cascade, and ultimately leads to less contracture, in an animal model. Methods A total of 18 rabbits underwent an operation on their right knees to form contractures. Six limbs in group 1 received four intra-articular injections of decorin; six limbs in group 2 received four intra-articular injections of bovine serum albumin (BSA) over eight days; six limbs in group 3 received no injections. The contracted limbs of rabbits in group 1 were biomechanically and genetically compared with the contracted limbs of rabbits in groups 2 and 3, with the use of a calibrated joint measuring device and custom microarray, respectively. Results There was no statistical difference in the flexion contracture angles between those limbs that received intra-articular decorin versus those that received intra-articular BSA (66° vs 69°; p = 0.41). Likewise, there was no statistical difference between those limbs that received intra-articular decorin versus those who had no injection (66° vs 72°; p = 0.27). When compared with BSA, decorin led to a statistically significant increase in the mRNA expression of 12 genes (p < 0.01). In addition, there was a statistical change in the mRNA expression of three genes, when compared with those without injection. Conclusions In this model, when administered intra-articularly at eight weeks, 2 mg of decorin had no significant effect on joint contractures. However, our genetic analysis revealed a significant alteration in several fibrotic genes. Cite this article: Bone Joint Res 2014;3:82–8.
Ureaplasma parvum Prosthetic Joint Infection Detected by PCR
Larson, Joshua A., Akeson, Jeffrey W., Lowery, Kristin S., Rounds, Megan A., Sampath, Rangarajan , Patel, Robin , Farrell, John Joseph , Bonomo, Robert A. , Patel, Robin

Journal of Clinical Microbiology | March 27, 2014 | Volume: 52 | Issue: 6 | Pages: 2248-2250

10.1128/jcm.00432-14 | PMID 24671783 Get It

ABSTRACT We describe the first reported case of Ureaplasma parvum prosthetic joint infection (PJI) detected by PCR. Ureaplasma species do not possess a cell wall and are usually associated with colonization and infection of mucosal surfaces (not prosthetic material). U. parvum is a relatively new species name for certain serovars of Ureaplasma urealyticum , and PCR is useful for species determination. Our patient presented with late infection of his right total knee arthroplasty. Intraoperative fluid and tissue cultures and pre- and postoperative synovial fluid cultures were all negative. To discern the pathogen, we employed PCR coupled with electrospray ionization mass spectrometry (PCR/ESI-MS). Our patient's failure to respond to empirical antimicrobial treatment and our previous experience with PCR/ESI-MS in culture-negative cases of infection prompted us to use this approach over other diagnostic modalities. PCR/ESI-MS detected U. parvum in all samples. U. parvum -specific PCR testing was performed on all synovial fluid samples to confirm the U. parvum detection.
Device lead-induced tricuspid regurgitation: does it matter?
Lin, Grace , Brady, Peter A.

Heart | March 26, 2014 | Volume: 100 | Issue: 12 | Pages: 900-901

10.1136/heartjnl-2013-305459 | PMID 24670417 Get It

Comparative Uterotrophic Effects of Endoxifen and Tamoxifen in Ovariectomized Sprague-Dawley Rats
Schweikart, Karen, Eldridge, Sandy , Safgren, Stephanie L. , Parman, Toufan, Ames, Matthew M. , Davis, Myrtle A., Reid, Joel M. , Goetz, Matthew P. , Safgren, Stephanie L

Toxicologic Pathology | March 26, 2014 | Volume: 42 | Issue: 8 | Pages: 1188-1196

10.1177/0192623314525688 | PMID 24670817 Get It

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen), one of the major active metabolites of tamoxifen, has substantially greater estrogen antagonist properties and antiproliferative effects in breast tumor cells than tamoxifen, a mixed estrogen agonist/antagonist. An associated risk of endometrial cancer and hyperplasia has been linked to the estrogen agonist properties of tamoxifen. We evaluated endoxifen using a classic uterotrophic effects method. Rats were given endoxifen or tamoxifen orally for 3 days. Estradiol was the positive control. Endoxifen and tamoxifen plasma levels exceeded those previously observed clinically. Uterine weight was 3-fold higher in the estradiol group than in the tamoxifen or endoxifen groups, which did not differ from vehicle controls. Tamoxifen and endoxifen caused a greater increase in luminal epithelial cell height than estradiol. Both tamoxifen and endoxifen produced an increase in the stromal BrdU labeling index (LI) that was ≤ estradiol and inversely related to dose, but did not affect luminal epithelial cell BrdU LI. As expected, estradiol increased luminal epithelial cell proliferation. These results indicate that endoxifen induces uterotrophic effects, but is less potent than estradiol in eliciting these effects. Given prior preclinical observations that endoxifen has superior antitumor activity than tamoxifen, the observations of similar uterine effects suggest that the endoxifen risk/benefit ratio may be superior to tamoxifen.
Boceprevir in liver transplant recipients
Saab, Sammy , Manne, Vignan, Bau, Sherona, Reynolds, Justin, Allen, Ruby, Durazo, Francisco , El-Kabany, Mohammed M., Han, Steven, Busuttil, Ronald W. , Goldstein, Leonard D.

Liver International | March 26, 2014 | Volume: 35 | Issue: 1 | Pages: 192-197

10.1111/liv.12548 | PMID 24673728 Get It

AbstractBackgroundThere has been increasing interest in using protease inhibitors with pegylated interferon and ribavirin to treat recurrent hepatitis C (HCV) disease in liver transplant recipients.MethodsWe retrospectively evaluated the safety and efficacy in liver transplant recipients treated for recurrent hepatitis C genotype 1 with the combination of peginterferon, ribavirin and boceprevir.ResultsTwenty liver transplant recipients were treated for recurrent hepatitis C. Baseline alanine aminotransferase, total bilirubin and HCV RNA values (± SD) were 67.5 (±50.9) mg/dl, 1.78 (±1.99) U/L, and 16 955 510 (±21 620 675) IU/ml. Anaemia was a common adverse event requiring epoetin in 16 of 20 recipients and ribavirin dose reductions in 17 of 20 recipients. One‐third of recipients required a blood transfusion. Filgrastim was used in 11 of 20 patients (55%) and eltrombopag in two of 20 recipients (10%) over the course of treatment. Serum creatinine level increased significantly from a baseline value of 1.33 mg/dl to 1.59 mg/dl at week 20 of boceprevir (P < 0.005). The overall sustained viral response (SVR) was 50%. Of the 14 patients who had a viral load less than 1000 IU/ml at week 4 of boceprevir, the SVR was 71%. The SVR was 83% of the 11 patients who had undetectable viral levels at week 4 of boceprevir.ConclusionsAntiviral therapy utilizing boceprevir in liver transplant recipients requires close monitoring. Anaemia and neutropenia were common requiring growth factors in most recipients. On‐treatment viral responses appear promising but long‐term data are needed.